{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:38:48Z","timestamp":1772505528894,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Actelion Pharmaceuticals US, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.rmed.2018.09.002","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:10:12Z","timestamp":1536106212000},"page":"139-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations"],"prefix":"10.1016","volume":"143","author":[{"given":"Sandra","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Kingman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribeth","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Clark","family":"Berngard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25 Suppl","key":"10.1016\/j.rmed.2018.09.002_bib1","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.rmed.2018.09.002_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.rmed.2018.09.002_bib3","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.rmed.2018.09.002_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1183\/09059180.00008211","article-title":"REVEAL: a contemporary US pulmonary arterial hypertension registry","volume":"21","author":"McGoon","year":"2012","journal-title":"Eur. Respir. Rev."},{"issue":"3","key":"10.1016\/j.rmed.2018.09.002_bib5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/2045893217719250","article-title":"Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension","volume":"7","author":"Kingman","year":"2017","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.rmed.2018.09.002_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40264-015-0365-x","article-title":"Comparative safety and tolerability of prostacyclins in pulmonary hypertension","volume":"39","author":"O'Connell","year":"2016","journal-title":"Drug Saf."},{"key":"10.1016\/j.rmed.2018.09.002_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0031-6997(25)06809-7","article-title":"Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology","volume":"46","author":"Rubanyi","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.rmed.2018.09.002_bib8","unstructured":"Tracleer\u00ae [package Insert]. Actelion Pharmaceuticals Ltd, Allschwil, Switzerland: September, 2017."},{"key":"10.1016\/j.rmed.2018.09.002_bib9","unstructured":"Letairis\u00ae [package Insert]. Gilead Sciences FC, CA; October 2015."},{"key":"10.1016\/j.rmed.2018.09.002_bib10","unstructured":"Opsumit\u00ae [prescribing Information. Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; March, 2017]."},{"key":"10.1016\/j.rmed.2018.09.002_bib11","unstructured":"Flolan\u00ae [package Insert]. GlaxoSmithKline RTP, NC; April, 2015."},{"key":"10.1016\/j.rmed.2018.09.002_bib12","unstructured":"Veletri\u00ae [package Insert]. Actelion Pharmaceuticals Ltd A, Switzerland; June, 2012."},{"key":"10.1016\/j.rmed.2018.09.002_bib13","unstructured":"Remodulin\u00ae [prescribing Information]. United Therapeutics Corporation, Research Triangle Park, NC; December, 2014."},{"key":"10.1016\/j.rmed.2018.09.002_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ccm.2013.09.003","article-title":"Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension","volume":"34","author":"McLaughlin","year":"2013","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.rmed.2018.09.002_bib15","unstructured":"Orenitram\u00ae [prescribing Information]. United Therapeutics Corporation, Research Triangle Park, NC; January 2017."},{"key":"10.1016\/j.rmed.2018.09.002_bib16","unstructured":"Tyvaso\u00ae [prescribing Information]. United Therapeutics Corporation, Research Triangle Park, NC; October 2017."},{"key":"10.1016\/j.rmed.2018.09.002_bib17","unstructured":"Ventavis\u00ae [prescribing Information]. Actelion Pharmaceuticals US, Inc., South San Francisco, CA; October 2017."},{"key":"10.1016\/j.rmed.2018.09.002_bib18","unstructured":"Uptravi\u00ae [prescribing Information]. Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; July 2017."},{"key":"10.1016\/j.rmed.2018.09.002_bib19","unstructured":"Adempas\u00ae [prescribing Information]. Bayer Pharmaceuticals, Leverkusen, Germany; February 2017."},{"key":"10.1016\/j.rmed.2018.09.002_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.vph.2006.03.004","article-title":"Does rapid dose titration affect the hepatic safety profile of Bosentan?","volume":"44","author":"Suntharalingam","year":"2006","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.rmed.2018.09.002_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2009.07.015","article-title":"A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension","volume":"104","author":"Mubarak","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2018.09.002_bib22","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.rmed.2018.09.002_bib23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/NAN.0000000000000017","article-title":"Management of the patient with pulmonary arterial hypertension receiving intravenous prostacyclin: an expert nurse practical guide","volume":"37","author":"Kingman","year":"2014","journal-title":"J. Infusion Nurs."},{"key":"10.1016\/j.rmed.2018.09.002_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1183\/16000617.0083-2016","article-title":"Practical considerations for therapies targeting the prostacyclin pathway","volume":"25","author":"Farber","year":"2016","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2018.09.002_bib25","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0735-1097(99)00320-4","article-title":"The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension","volume":"34","author":"Rich","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.rmed.2018.09.002_bib26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.chest.2018.03.050","article-title":"Mortality in patients with pulmonary arterial hypertension treated with continuous prostanoids","volume":"154","author":"Bartolome","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2018.09.002_bib27","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2165\/11638260-000000000-00000","article-title":"Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations","volume":"72","author":"Skoro-Sajer","year":"2012","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.rmed.2018.09.002_bib28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000450759","article-title":"Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial","volume":"92","author":"Gr\u00fcnig","year":"2016","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2018.09.002_bib29","article-title":"The Delphi Process in the creation of a consensus statement for practical use of orenitram","volume":"191","author":"Rahaghi","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.09.002_bib30","doi-asserted-by":"crossref","first-page":"1A","DOI":"10.1016\/j.amjcard.2012.12.002","article-title":"Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies","volume":"111","author":"Waxman","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.rmed.2018.09.002_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1513\/AnnalsATS.201501-020AS","article-title":"Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration","volume":"12","author":"Hill","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.rmed.2018.09.002_bib32","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1080\/14656566.2016.1215429","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"17","author":"Richter","year":"2016","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.rmed.2018.09.002_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"20","key":"10.1016\/j.rmed.2018.09.002_bib34","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil use in pulmonary arterial hypertension (SUPER) study Group. Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.rmed.2018.09.002_bib35","first-page":"2894","article-title":"Pulmonary arterial hypertension and response to tadalafil (PHIRST) study Group. Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.rmed.2018.09.002_bib36","unstructured":"Revatio\u00ae [prescribing Information]. Pfizer Inc., New York, NY; March 2014."},{"key":"10.1016\/j.rmed.2018.09.002_bib37","unstructured":"Adcirca\u00ae [prescribing Information]. Eli Lilly and Company, Indianaplis, IN: August 2017."},{"issue":"9","key":"10.1016\/j.rmed.2018.09.002_bib38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.09.002_bib39","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/phar.1592","article-title":"Riociguat: a novel new drug for treatment of pulmonary hypertension","volume":"35","author":"Makowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rmed.2018.09.002_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.rmed.2017.05.005","article-title":"Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"129","author":"Hill","year":"2017","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.09.002_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1183\/09031936.00194909","article-title":"Six Minute Walk Distance Project (ALAT). The 6-min walk distance in healthy subjects: reference standards from seven countries","volume":"37","author":"Casanova","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.09.002_bib42","first-page":"S3","article-title":"The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management","volume":"22","author":"Burger","year":"2016","journal-title":"Am. J. Manag. Care"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118302841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118302841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:47:11Z","timestamp":1760615231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611118302841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":42,"alternative-id":["S0954611118302841"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.09.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}